Archives of Pediatric Infectious Diseases

Published by: Kowsar

The Acute Effect of Inhaled NaCl 5%, Per CF TRUST Protocol, on Spirometry Indices in Patients Over Six Years with Cystic Fibrosis

Seyed-Ahmad Tabatabaei 1 , Gholamreza Panahandeh 2 , * , Ghamartaj Khanbabaei 1 and Saeid Sadr 3
Authors Information
1 Associate Professor, Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Assistant Professor, Department of Pediatrics, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
3 Assistant Professor, Department of Pediatrics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Pediatric Infectious Diseases: April 2018, 6 (2); e12063
  • Published Online: March 11, 2018
  • Article Type: Research Article
  • Received: February 25, 2017
  • Revised: November 6, 2017
  • Accepted: November 13, 2017
  • DOI: 10.5812/pedinfect.12063

To Cite: Tabatabaei S, Panahandeh G, Khanbabaei G, Sadr S. The Acute Effect of Inhaled NaCl 5%, Per CF TRUST Protocol, on Spirometry Indices in Patients Over Six Years with Cystic Fibrosis, Arch Pediatr Infect Dis. 2018 ;6(2):e12063. doi: 10.5812/pedinfect.12063.

Abstract
© 2018, Archives of Pediatric Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnote
References
  • 1. National Center for Biotechnology Information. Genes and Disease. Cystic fibrosis. USA: National Center for Biotechnology Information (US); 2011.
  • 2. Thibodeau PH, Richardson J3, Wang W, Millen L, Watson J, Mendoza JL, et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem. 2010;285(46):35825-35. doi: 10.1074/jbc.M110.131623. [PubMed: 20667826].
  • 3. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care. 2009;54(5):595-605. [PubMed: 19393104].
  • 4. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157-70. doi: 10.1146/annurev.med.58.071905.105316. [PubMed: 17217330].
  • 5. Reeves EP, McCarthy C, McElvaney OJ, Vijayan MS, White MM, Dunlea DM, et al. Inhaled hypertonic saline for cystic fibrosis: Reviewing the potential evidence for modulation of neutrophil signalling and function. World J Crit Care Med. 2015;4(3):179-91. doi: 10.5492/wjccm.v4.i3.179. [PubMed: 26261770].
  • 6. Button BM, Button B. Structure and function of the mucus clearance system of the lung. Cold Spring Harb Perspect Med. 2013;3(8). doi: 10.1101/cshperspect.a009720. [PubMed: 23751214].
  • 7. Ong T, Ramsey BW. Modifying disease in cystic fibrosis: current and future therapies on the horizon. Curr Opin Pulm Med. 2013;19(6):645-51. doi: 10.1097/MCP.0b013e328365ab5f. [PubMed: 24048086].
  • 8. Dentice RL, Elkins MR, Bye PT. Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. J Physiother. 2012;58(1):33-40. doi: 10.1016/S1836-9553(12)70070-X. [PubMed: 22341380].
  • 9. Elkins M, Dentice R. Timing of hypertonic saline inhalation for cystic fibrosis. Cochrane Database Syst Rev. 2012;(2). CD008816. doi: 10.1002/14651858.CD008816.pub2. [PubMed: 22336853].
  • 10. Elkins MR, Bye PT. Mechanisms and applications of hypertonic saline. J R Soc Med. 2011;104 Suppl 1:S2-5. doi: 10.1258/jrsm.2011.s11101. [PubMed: 21719889].
  • 11. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229-40. doi: 10.1056/NEJMoa043900. [PubMed: 16421364].
  • 12. Enderby B, Doull I. Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?. Arch Dis Child. 2007;92(3):195-6. doi: 10.1136/adc.2006.094979. [PubMed: 17337677].
  • 13. Marson FA, Hortencio TD, Aguiar KC, Ribeiro JD, Cyfiuc Group . Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. BMC Pulm Med. 2015;15:3. doi: 10.1186/1471-2466-15-3. [PubMed: 25592785].
  • 14. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972-9. [PubMed: 14680088].
  • 15. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106(5):661-7. doi: 10.1016/j.rmed.2011.12.021. [PubMed: 22349069].
  • 16. Rosenfeld M, Davis S, Brumback L, Daniel S, Rowbotham R, Johnson R, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol. 2011;46(7):666-71. doi: 10.1002/ppul.21425. [PubMed: 21365779].
  • 17. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):134-9. 139 e1. doi: 10.1016/j.jpeds.2007.03.006. [PubMed: 17643762].
  • 18. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell. 2001;8(1):149-58. [PubMed: 11511368].
  • 19. Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003;361(9358):681-9. doi: 10.1016/S0140-6736(03)12567-6. [PubMed: 12606185].
  • 20. Reeves EP, Molloy K, Pohl K, McElvaney NG. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. ScientificWorldJournal. 2012;2012:465230. doi: 10.1100/2012/465230. [PubMed: 22645424].
  • 21. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 Suppl):1S-39S. [PubMed: 14734689].
  • 22. Stainforth JN, Lewis RA, Tattersfield AE. Dosage and delivery of nebulised beta agonists in hospital. Thorax. 1983;38(10):751-4.
  • 23. Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev. 2005;(4). CD003428. doi: 10.1002/14651858.CD003428.pub2. [PubMed: 16235319].
  • 24. Hughes T, Clifton IJ, Peckham DG, Etherington C, Pollard K, Conway SP. 191 A retrospective study to assess the response to nebulised salbutamol during a period of stability in adult patients with Cystic Fibrosis. J Cystic Fibrosis. 2006;5. S44. doi: 10.1016/s1569-1993(06)80173-6.

Altmetric:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Comments